🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million infections per year. Particularly high rates are seen in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Data and Global Access

Based on data detailed in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an equal footing with the typical regimen, which combines an injection and a pill. The study included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed hope. Access to a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is considered crucial to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea globally.